高级检索
当前位置: 首页 > 详情页

Retroperitoneal extragastrointestinal stromal tumors have a poor survival outcome: A multicenter observational study(Open Access)

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of General Surgery, GuangdongProvincial People’s Hospital, GuangdongAcademy of Medical Sciences, Guangzhou,Guangdong 510080, People’s Republic of China [2]Department of Bariatric and Metabolic Surgery,Klinikum Ernst von Bergmann, Potsdam 14467,Germany [3]Department of Gastric Cancer,Cancer Hospital of China Medical University,Liaoning Cancer Hospital and Institute,Shenyang, Liaoning 110042, People’s Republic ofChina [4]Department of Gastrointestinal Surgery,Guangdong Provincial Hospital of ChineseMedicine, The Second Affiliated Hospital ofGuangzhou University of Chinese Medicine,Guangzhou 510120, People’s Republic of China [5]Department of Gastric Surgery, Fujian MedicalUniversity Union Hospital, Fuzhou, Fujian350001, People’s Republic of China
出处:
ISSN:

关键词: Disease-free survival Extra gastrointestinal stromal tumors Gene mutation Immunohistopathology Multicenter National Institutes of Health criteria Overall survival Recurrence Retroperitoneum Risk factor

摘要:
Purpose: Gastrointestinal stromal tumors (GISTs) are commonly known to be derived from the gastrointestinal (GI) tract, but recently there have been more and more literature describing lesions with similar pathological and immunohistochemical resembling GISTs but located outside the GI tract, and they have been termed as extra-GISTs (eGISTs). However, due to the rare incidence of eGISTs, its association with survival outcomes is poorly understood, espe-cially in the Chinese population. Here, we aimed to identify the risk factors of eGISTs and to assess their association with overall survival (OS) and disease-free survival (DFS). Patients and Methods: Data of pathologically confirmed eGISTs cases, without radiolo-gical and perioperative evidence of other primary lesions, and with no microscopically identified adhesion between the tumor and the gastrointestinal serosa, which were surgically treated between January 2006 and September 2017 were retrieved from the database of four high-volume hospitals. Immunohistochemical and genetic testing were performed on the postoperative lesions and were staged using the National Institutes of Health (NIH) criteria. Results: A total of 55 cases were retrieved. eGISTs were identified from the retroperitoneum (36.4%), mesocolon (25.5%), small bowel mesentery (12.7%), abdominopelvic cavity (12.7%), lesser omental sac (5.5%), ovary (3.6%), pancreatic capsule (1.8%), or urinary bladder (1.8%). Based on the NIH risk classification, majority of the lesion were classified as high risk (85.5%). KIT 11 was the most common mutation site (76.5%) and 25.0% of the cases were wild-type eGISTs. Multivariate analyses showed that tumor location and size were independent factors affecting prognoses. Patients with tumors in the retroperitoneum had significantly poorer OS and DFS as compared to those in the non-retroperitoneum (HR [95% CI] for OS and DFS: 2.546 [1.023–6.337] [P = 0.037] and 2.475 [0.975–6.273] [P = 0.049], respectively). Similar findings were found for tumors of size >15 cm, compared to ≤15 cm (HR [95% CI] for OS and DFS: 5.350 [2.022–14.156] [P<0.001] and 3.861 [1.493–9.988] [P = 0.003], respectively). Conclusion: eGISTs were predominantly found from the retroperitoneum and mostly classified as high risk. Those located in the retroperitoneum and of size >15 cm had the poorer OS and DFS as compared to those in the non-retroperitoneum and of size <15 cm. © 2020 Hu et al.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2018]版:
Q3 ONCOLOGY
最新[2023]版:
Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Department of General Surgery, GuangdongProvincial People’s Hospital, GuangdongAcademy of Medical Sciences, Guangzhou,Guangdong 510080, People’s Republic of China
共同第一作者:
通讯作者:
通讯机构: [1]Department of General Surgery, GuangdongProvincial People’s Hospital, GuangdongAcademy of Medical Sciences, Guangzhou,Guangdong 510080, People’s Republic of China [3]Department of Gastric Cancer,Cancer Hospital of China Medical University,Liaoning Cancer Hospital and Institute,Shenyang, Liaoning 110042, People’s Republic ofChina [*1]Department of General Surgery, Guangdong Provincial People’s Hospital , Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou, Guangdong 510080, People’s Republic of China [*2]Department of Gastric Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, People’s Republic of China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号